Tetrabenazine acts by inhibiting: (A) MAO-B, (B) Vesicular monoamine transpoer, (C) Dopamine D2 receptors, (D) COMT
Answer is B. Tetrabenazine: Inhibit VMAT 2(vesicular monoamine transpoer), which transpo dopamine and norepinephrine into adrenergic vesicle in nerve ending. Use for treatment of chorea in Huntington and tardive dyskinesia. In above figure: Pharmacologic strategies for dopaminergic therapy of Parkinson's disease. Drugs and their effects are indicated (see text). MAO, monoamine oxidase; COMT, catechol-O-methyltransferase; DOPAC, dihydroxyphenylacetic acid; L-DOPA, levodopa; 3-OMD, 3-O-methydopa; 3-MT, 3-methoxytramine.